Sign Up

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY) (the "Company" or "Femasys"), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 10,434,586 shares of its common stock, or in lieu thereof, pre-funded warrants to purchase up to 11,750,000 shares of its common stock, together with accompanying common warrants to purchase up to an aggregate of 22,184,586 shares of its common stock. The combined public offering price for each share of common stock and accompanying common warrant is $0.36, except for 87,363 shares and accompanying warrants sold to certain officers of the Company at a price of $0.5151 per share and accompanying warrant. The combined offering price of each pre-funded warrant and accompanying common warrant is $0.3599. Each accompanying common warrant will have an exercise price of $0.36, except for the warrants sold to certain officers of the Company which will have an exercise price of $0.5151. Each of the accompanying warrants will be immediately exercisable from the date of issuance and will expire five years from the date of issuance.

The gross proceeds from the offering to Femasys, before deducting the underwriting discounts and commissions and other public offering expenses payable by Femasys, are expected to be approximately $8.0 million. Femasys intends to use the net proceeds from the offering for expansion of commercial efforts, development of its products and product candidate, general corporate purposes, capital expenditures, working capital and general and administrative expenses. All of the securities are to be sold by the Company. The offering is expected to close on or about August 27, 2025, subject to satisfaction of customary closing conditions.

Jones and Laidlaw & Company (UK) Ltd. are acting as joint book-running managers for the offering.

The securities offered in the offering are being offered by the Company pursuant to a Registration Statement on Form S-1 (File No. 333-289722) (as amended to date, the "Registration Statement") previously filed ...